09:46 AM EST - Trillium Therapeutics Inc. : Has advanced its novel investigational drug TTI-621, a SIRPa-IgG1 Fc fusion protein, from dose escalation into Phase 1b cohort expansion enrollment in patients with advanced hematologic malignancies. Trillium Therapeutics Inc.
shares T.TR are trading up $0.44 at $18.79.
